Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 28, Number 5—May 2022

SARS-CoV-2 Antibody Prevalence and Population-Based Death Rates, Greater Omdurman, Sudan

Wendelin Moser, Mohammed Ahmed Hassan Fahal1, Elamin Abualas1, Shahinaz Bedri, Mahgoub Taj Elsir, Mona Fateh El Rahman Omer Mohamed, Abdelhalim Babiker Mahmoud, Amna Ismail Ibrahim Ahmad, Mohammed A. Adam, Sami Altalib, Ola Adil DafaAllah, Salahaldin Abdallah Hmed, Andrew S. Azman, Iza Ciglenecki, Etienne Gignoux, Alan González, Christine Mwongera, and Manuel Albela MirandaComments to Author 
Author affiliations: Médecins Sans Frontières, Geneva, Switzerland (W. Moser, A.S. Azman, I. Ciglenecki, A. González, C. Mwongera, M. Albela Miranda); Médecins Sans Frontières, Khartoum (M.T. Elsir, A.B. Mahmoud, A.I.I. Ahmad, M.A. Adam, S. Altalib, O.A. DafaAllah, S.A. Hmed); Khartoum State Ministry of Health, Khartoum, Sudan (M.AH. Fahal, E. Abualas, S. Bedri, M.T. Elsir, M.F.E.R.O. Mohamed, O.A. DafaAllah); National Public Health Laboratory, Khartoum (E. Abualas, S. Bedri, O.A. DafaAllah); University of Khartoum, Khartoum (A.B. Mahmoud, M.A. Adam, S. Altalib); Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA (A.S. Azman); University of Geneva, Geneva (A.S. Azman); Epicentre, Paris, France (E. Gignoux)

Main Article

Table 1

SARS-CoV-2 antibody seroprevalence test results by age group in cross-sectional survey, Omdurman, Sudan*

Age group RDT results
Adjusted results
% Positive (95% CI) Relative risk (95% CI) p value† Seroprevalence (95% CI) Relative risk (95% CI) p value†
<5 y, = 299 18.7 (14.7–23.5) 0.4 (0.3–0.5) <0.001 29.0 (22.4–36.9) 0.3 (0.3–0.4) <0.001
5–19 y, = 786 30.6 (27.5–33.9) 0.6 (0.5–0.7) <0.001 48.5 (43.3–53.9) 0.6 (0.5–0.6) <0.001
20–34 y, = 629 35.5 (31.8–39.3) 0.7 (0.6–0.8) <0.001 56.5 (50.5–62.8) 0.7 (0.6–0.7) <0.001
35–49 y, = 342 39.5 (34.4–44.7) 0.8 (0.7–0.9) 0.006 63.1 (54.8–71.8) 0.8 (0.7–0.9) <0.001
>50 y, = 319
50.2 (44.7–55.6)

80.7 (71.7–89.7)
Overall, = 2,375 34.3 (32.4–36.2)
54.6 (51.4–57.8)

*RDT, rapid diagnostic test; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2. †p values indicate the difference in relative risk between the oldest age group (≥50 y) as reference and the other age groups.

Main Article

1These authors contributed equally to this article.

Page created: March 28, 2022
Page updated: April 19, 2022
Page reviewed: April 19, 2022
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.